trending Market Intelligence /marketintelligence/en/news-insights/trending/gfoxmdjr2wlltls130fbyq2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Biogen secures US FDA approval for spinal muscular atrophy treatment

State Of Singapore Online Video Subscription

Power Forecast Briefing: Capacity Shortfalls to Test the Renewable Energy Transition

Episode 43 - More Change, M&A On Horizon For Equity Research Industry

Cable Nets Struggle With Little Revenue Growth Expanding Programming Budgets


Biogen secures US FDA approval for spinal muscular atrophy treatment

Biogen Inc. said it received U.S. FDA approval for SPINRAZA, a treatment for spinal muscular atrophy.

The drug was approved following positive results from multiple clinical studies in more than 170 patients. In a controlled clinical study, those treated with the drug showed clinically meaningful improvements in their motor functions. Also, a greater percentage of patients on the drug survived compared to untreated patients.

Biogen plans to make the drug available for shipment in the U.S. to healthcare providers in about a week.